Phencyclidine (PCP) is believed to be the first arylcyclohexylamine with recognized anesthetic properties, but several arylcyclohexylamines were described before PCP in the scientific literature, beginning with PCA (1-phenylcyclohexan-1-amine) the synthesis of which was first published in 1907. We reported PCE in 1953 and PCMo in 1954, with the latter compound described as a potent sedative. Buy arylcyclohexylamines online, Arylcyclohexylamine anesthetics were intensively investigated at Parke-Davis, beginning with the 1956 synthesis of phencyclidine and later the related compound ketamine. The 1970s saw the debut of these compounds, especially PCP and its analogues, as illicitly used recreational drugs because of their dissociative hallucinogenic and euphoriant effects. Since scientific research into stimulant, analgesic, and neuroprotective agents has expanded the class, and also by clandestine chemists in search of novel recreational drugs, Buy arylcyclohexylamines online.
Buy arylcyclohexylamines online for Pharmacology
Arylcyclohexylamines varyingly possess NMDA receptor antagonistic, dopamine reuptake inhibitory, and μ-opioid receptor agonistic properties. Σ receptor agonistic, nACh receptor antagonistic, and D2 receptor we have reported agonistic actions for some of these agents. Antagonism of the NMDA receptor confers anesthetic, anticonvulsant, neuroprotective, and dissociative effects; blockade of the dopamine transporter mediates stimulant and euphoriant effects and psychosis in high amounts; and activation of the μ-opioid receptor causes analgesic and euphoriant effects. Stimulation of the σ and D2 receptors may also contribute to hallucinogenic and psychomimetic effects.These are versatile agents with a wide range of possible pharmacological activities, depending on the extent and range to which chemical modifications are implemented.The various choice of substitutions that are made allows for “fine-tuning” of the pharmacological profile that results. Buy arylcyclohexylamines online As examples, BTCP is a selective dopamine reuptake inhibitor, PCP is primarily an NMDA antagonist, and BDPC is a potent μ-opioid agonist, while PRE-084 is a selective sigma receptor agonist. Thus, radically different pharmacology is possible through different structural combinations.